Spectranetics is among three medical technology companies that will benefit from increasing competition in the sector this year, Citi analyst Amit Bhalla predicted in a note to clients recently.
Bhalla expects strong upcoming quarters from Spectranetics because of the rollout of its Turbo Booster catheter for treatment of blockages in upper leg arteries. He also expects strong upcoming quarters from cancer therapy system manufacturer Varian Medical Systems Inc. and strong earnings in the first quarter and all of 2oo8 from Hologic Inc. with its digital mammography system driving revenue.
Bhalla maintained his$19 price target and a "speculative buy" rating for Spectranetics.
For more information on Spectranetics, go to http://www.spectranetics.com/.